human coagulation factor ix

Trade name: Mononine

Recombinant proteinapprovedOrphan Drug FDA

Approved

Dec 31, 1990

Factor IX, also known as Christmas factor, is one of the serine proteases involved in coagulation; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B. — Wikipedia

Clinical trial activity

15 trials · 15 clinical orgs · 3 marketing orgs

Phase 1
5
Phase 2
9
Phase 3
6
Phase 4
3

Earliest trial started Mar 1, 1992 (NCT00004801)

Timeline

1980s

  1. Jun 27, 1989

    Orphan Drug Designation

1990s

  1. Dec 31, 1990

    Earliest FDA Approval

  2. Dec 31, 1990

    Grifols — NDA Secondary Org

  3. Jan 1, 1992

    Earliest Phase 1 Sponsor(trial)

  4. Jan 1, 1997

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Mar 17, 2000

    CSL Behring — NDA Secondary Org

2010s

  1. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 31, 1990

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4f-pcc
  • alphanine
  • alphanine
  • alphanine sd
  • antihemophilic factor
  • antihemophilic factor/von willebrand factor complex (human)
  • coagulation factor ix
  • coagulation factor ix
  • coagulation factor ix
  • coagulation factor ix human
  • coagulation factor ix (human)
  • coagulation factor ix (human)
  • coagulation factor ix, ii, vii and x in combination
  • factor ix
  • factor ix fraction
  • factor ix fraction
  • factor viii - von willebrand factor
  • factor viii, von willebrand factor drug combination
  • human coagulation factor ix
  • human coagulation factor ix
  • human coagulation factor ix
  • konyne 80
  • mononine
  • mononine
  • octocog alfa
  • pcc
  • pcc
  • plasma concentrate factor ix
  • plasma concentrate factor ix
  • profilate heat-treated
  • profilate hp
  • profilate osd
  • profilate sd
  • profilnine
  • profilnine sd
  • replenine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05281718Early Phase 1 (Phase 1)Aug 1, 2022Genentech, Tulane University
NCT03995784Phase 2Jun 18, 2019Catalyst Biosciences
NCT02695160Phase 1Jun 1, 2016Sangamo BioSciences
NCT01687608Phase 1/Phase 2 (Phase 2)Sep 1, 2012Baxalta
NCT01440946Phase 3Jun 1, 2012Biogen, Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum
NCT01233440Phase 1Oct 1, 2010CSL Behring
NCT01128881Phase 4May 1, 2010Baxalta
NCT02250573Phase 3Dec 1, 2005Bio Products Laboratory
NCT02263469Phase 3Aug 1, 2005Bio Products Laboratory
NCT00139828Phase 4May 1, 2003Sanquin, Utrecht University
NCT02250560Phase 3Apr 1, 2000Bio Products Laboratory
NCT01561391Phase 4Apr 1, 1998Novo Nordisk
NCT02231944Phase 3Jul 1, 1997Bio Products Laboratory
NCT02263456Phase 3Jul 1, 1997Bio Products Laboratory
NCT00004801Phase 1/Phase 2 (Phase 2)Mar 1, 1992National Center for Research Resources (NCRR), University of North Carolina at Chapel Hill
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (15)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bio Products LaboratoryFor profit5511997
BaxaltaFor profit2222010
BiogenFor profit1012012
Bioverativ Therapeutics Inc.For profit1112012
Catalyst BiosciencesFor profit1112019
CSL BehringFor profit1112010
GenentechFor profit1012022
National Center for Research Resources (NCRR)Government1111992
Novo NordiskFor profit1111998
Sangamo BioSciencesFor profit1112016
SanquinAcademic/Hospital1112003
Swedish Orphan BiovitrumFor profit1012012
Tulane UniversityAcademic/Hospital1112022
University of North Carolina at Chapel HillAcademic/Hospital1011992
Utrecht UniversityAcademic/Hospital1012003
15 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
BaxaltaFor profitNDA
CSL BehringFor profitNDA2Mar 17, 2000
GrifolsFor profitNDA2Dec 31, 1990